Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Integrin + dacarbazine
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Dacarbazine is a synthetic antineoplastic agent classified as an alkylating agent and used primarily in the treatment of metastatic malignant melanoma and Hodgkin's disease. It acts as a prodrug that is metabolized in the liver to its active form, methyltriazenoimidazole carboxamide (MTIC), which exerts cytotoxic effects mainly through DNA methylation and inhibition of DNA synthesis. Integrins are not a drug but rather a large family of heterodimeric transmembrane receptors involved in cell adhesion, migration, angiogenesis, immune cell invasion, and signal transduction. They are considered important drug targets in cancer therapy due to their role in tumor progression and metastasis. The combination "integrin + dacarbazine" refers to investigational or experimental regimens where integrin inhibitors (not specified here) may be combined with dacarbazine for synergistic anti-tumor effects; however, "integrin" itself is not an approved pharmaceutical product[1][2][3][4][5][6][8].
- Brand names
- Dacarbazine for Injection
- Other names
- integrindacarbazine
02
Targets
ITGAV (Integrin αV)DNA
Beyond the preview
Go deeper on Integrin + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Integrin + dacarbazine.